Leading areas of investigation, endpoints and intervention types in adaptive trials
| Area of investigation | Number of trials |
| Oncology | 28/142 (20%) |
| Infectious diseases | 18/142 (13%) |
| Circulatory system disorders | 14/142 (10%) |
| Nervous system diseases | 14/142 (10%) |
| Other diseases/disorders | 68/142 (48%) |
| Endpoints | Number of trials |
| Surrogate measures | 25/142 (18%) |
| Clinical endpoints | 38/142 (27%) |
| Surrogate measures and clinical endpoints | 79/142 (56%) |
| Type of intervention | Number of trials |
| Drugs | 121/142 (85%) |
| Other therapies | 13/142 (9%) |
| Medical devices | 9/142 (6%) |